BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, May 7, 2026
Home » Topics » Briefs

Briefs
Briefs RSS Feed RSS

Other news to note for Feb. 28, 2023

Feb. 28, 2023
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Adimmune, Biocytogen, Biosenic, Celltrion Healthcare, Chipscreen, Clover, Cue, Essex Bio-Technology, Fatiabgen, Gilead Sciences, Kinnate, Kinnjiu, Liscure, Myeloid, Ono, Ordaōs, Shanghai Henlius, Shenzhen Pregene.
Read More

In the clinic for Feb. 21-27, 2023

Feb. 28, 2023
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Alteogen, Amniotics, Ascletis, Aslan, Astellas, Atea, Bridge, Effector, Horizon, Innocare, Junshi, Keymed, Kinarus, Merck, Neurophth, Oscotec, Shionogi, Shionogi, Takeda, Telix, Westvac.
Read More

Financings for Feb. 28, 2023

Feb. 28, 2023
Biopharmas in Asia-Pacific raising money in public or private financings: Aslan.
Read More

Regulatory actions for Feb. 28, 2023

Feb. 28, 2023
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Elekta, Hyperfine, Milestone Scientific.
Read More

Other news to note for Feb. 28, 2023

Feb. 28, 2023
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Beauty Health, Bioventus, Diasorin, Cytek, Egnite, Establishment Labs, Luminex, Nanospot, Prelude, Sophia Genetics, Synergy Laboratories.
Read More

In the clinic for Feb. 28, 2023

Feb. 28, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbott, Premia Spine, Pulnovo Medical.
Read More

Appointments and advancements for Feb. 28, 2023

Feb. 28, 2023
New hires and promotions in the med-tech industry, including: Geneoscopy, Nanalysis Scientific.
Read More

Regulatory actions for Feb. 28, 2023

Feb. 28, 2023
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Amo, Asklepios, Biophytis, Glaukos, Orchard, PDS, Priothera, Replimune, Springworks.
Read More

Other news to note for Feb. 28, 2023

Feb. 28, 2023
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adamis, Amarin, Catalyst, CSL, DMK, GC, Pfizer, Redhill, Sunshine, Tempus, Tevard, Theravance, Vertex.
Read More

In the clinic for Feb. 28, 2023

Feb. 28, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Blueprint, Celldex, Chiesi, Clene, Elpiscience, Evelo, Hutchmed, Imunon, Levation, Maze, Mitsubishi Tanabe, Nexcella, Sanofi.
Read More
Previous 1 2 … 842 843 844 845 846 847 848 849 850 … 1791 1792 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 6, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 5, 2026
  • Strategy compass

    Bio Korea 2026: US policy risks shift to execution framework

    BioWorld
    Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
  • The epidermal growth factor receptor in the inactive (left) and active (right) form.

    Cytospire raises £61M series A to target EGFR in solid tumors

    BioWorld
    Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
  • Regulatory actions for May 5, 2026

    BioWorld
    Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing